Beyond Air (NASDAQ:XAIR) Issues Earnings Results

Beyond Air (NASDAQ:XAIR) issued its quarterly earnings results on Wednesday. The company reported ($3.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.31) by ($0.45), Zacks reports. Beyond Air had a negative net margin of 435.71% and a negative return on equity of 440.26%.

Beyond Air Price Performance

Shares of NASDAQ:XAIR traded up $0.11 on Wednesday, reaching $2.63. 626,930 shares of the company traded hands, compared to its average volume of 182,259. Beyond Air has a fifty-two week low of $2.05 and a fifty-two week high of $53.20. The company’s 50 day moving average is $2.68 and its 200-day moving average is $9.55. The stock has a market capitalization of $2.52 million, a PE ratio of -0.04 and a beta of 0.23. The company has a debt-to-equity ratio of 7.81, a current ratio of 3.31 and a quick ratio of 3.12.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on XAIR. Weiss Ratings raised shares of Beyond Air from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. Lake Street Capital started coverage on shares of Beyond Air in a research report on Tuesday, September 1st. They set a “buy” rating and a $10.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $105.00.

About Beyond Air

Beyond Air, Inc. is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders. The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings. LungFit PH is designed to deliver inhaled nitric oxide to term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.